1.. Introduction
================

A large number of pregnant women need for termination of pregnancy (TOP) which is due to fetal anomalies, fetal death, or maternal diseases. Surgical interventions and medical treatments are used to achieve this aim. Medical treatment is more favorable treatment and is commonly used for TOP. Misoprostol, mifeprostol, and oxytocin are common drugs used alone or in combination for TOP. Misoprostol is a synthetic prostaglandin E1 analog which is used for TOP in various gestational ages (GA). Nausea and vomiting, diarrhea, and abdominal cramping are common side effects. Also its use in scarred uteruses is limited ([@b1-epj-05-713]). Also oxytocin is effectively used in combination with misoprostol in TOP ([@b2-epj-05-713]).

Second trimester TOP is associated with more complications in comparison to first trimester TOP. The rate of infection and the need for surgical intervention is higher in second trimester TOP ([@b3-epj-05-713]). Also a large number of curettage is reported after second trimester TOP ([@b4-epj-05-713]). Uterine rupture is less common but is reported in scarred and unscarred uteruses ([@b5-epj-05-713], [@b6-epj-05-713]). Also Morotti et al reported Defective Placental Adhesion as complication for TOP in second trimester ([@b7-epj-05-713]). The rate of complications of TOP in second trimester is reported to be 6% ([@b8-epj-05-713]). Higher gestational age fetal indication and history of curettage are important risk factors for complication ([@b8-epj-05-713]--[@b10-epj-05-713]). Several studies are done in order to obtain the most effective and safe regimen for medical treatment in TOP in second trimester. Misoprostol is reported to be a safe, effective, and acceptable treatment for second trimester TOP ([@b11-epj-05-713]). Also Ozerkan et al have reported higher effectiveness with no increase in side effects by using high dose of misoprostol ([@b12-epj-05-713]). Misoprostol is usually used vaginally but similar efficacy is reported for sublingual dosages ([@b13-epj-05-713], [@b14-epj-05-713]). Although adequate studies are available for comparison of different misoprostol regimens ([@b15-epj-05-713]--[@b18-epj-05-713]) and its combination with other treatments ([@b2-epj-05-713], [@b19-epj-05-713]--[@b22-epj-05-713]) but still studies are continuing to obtain the most effective regimen with less side effects and complications. Additional misoprostol dosages and oxytocin infusion or rarely hysterotomy is used for treatment of patients when TOP fails ([@b23-epj-05-713]). The aim of current study is to compare the efficacy of vaginal misoprostol versus oxytocin in second trimester TOP.

2.. Materials and Methods
=========================

This randomized single--blind controlled trial was conducted at the Shariati hospital, university of Hormozgan in Iran, from December 2010 to January 2012. Total of 120 women 18 to 40 years old with gestational age between 14 to 24 weeks were recruited to the study. Inclusion criteria were pregnant women in second trimester according to LMP or first trimester ultrasonography, who were referred to Shariati hospital for pregnancy termination due to missed abortion, intrauterine fetal death (IUFD), fetal abnormalities or genetic disorders such as major thalassemia, and maternal indication such as cardiac disease with closed cervix in the absence of uterine contractions.

The study was approved by ethics committee of Hormozgan University of Medical Sciences (HUMS) and patients were included in the study after obtaining written informed consent. The exclusion criteria were: chorioamniotitis, incomplete abortion, sever polyhydraminus, diabetes mellitus or hypertention, cerclage or previous cervix injuries, unsuccessful treatment for current pregnancy, placenta previa, and contraindications of prostaglandin use (cardiovascular diseases or hypersensitivity). Finally 100 patients were randomly assigned into two equal groups using random digit table either to receive high dose oxytocin and laminaria or misoprostol. For Patients in first group inserted laminaria intra cervical for 6 hours, then laminaria was removed and the patient received 50 unite oxytocin in 500cc normal saline for 3 hours. After one hour rest oxytocin dosage will be doubled. This increase will be continued up to 300 unite oxytocin in 500cc normal saline. Patients in second group received an initial dosage of 200 micrograms misoprostol intravaginal followed by the same dosage every 6 hours up to 48 hours. Treatment failure was defined as unsuccessful termination after 48 hour after laminaria insertion or misoprostol initial dose. Patients were treated using curettage, hysterectomy or additional misoprostol dosage in a case of incomplete fetal termination (residual placenta).

The primary outcome was treatment success rate; the secondary outcomes were duration of termination from treatment start to termination, complete or incomplete or no termination, need for supplementary methods (hysterectomy, courtage, or additional misoprostol dosage), and drug side effects (Fever, nausea and vomiting, diarrhea, and abdominal cramping). Data was analyzed using SPSS 20 software and descriptive statistics, Chi-Square, and independent samples t-test. A P value less than 0.05 was defined as statistically significant level for differences.

3.. Results
===========

One hundred patients were assigned into two equal groups with similar baseline characteristics. [Table 1](#t1-epj-05-713){ref-type="table"} summarized baseline characteristics of the patients in two groups. As shown in [Table 2](#t2-epj-05-713){ref-type="table"} rate of pregnancy termination was higher in misoprostol group (98%) in comparison to oxytocin group (56%) and percentage of incomplete termination was higher in misoprostol group than oxytocin group (60% vs. 20%) (P\<0.001). Mean duration of termination was 14.35±4.71 hours for misoprostol group and 21.85±4.96 for oxytocin group which shows a statistically significant shorter duration for in misoprostol group (P\<0.001). Drug side effects were reported in 23 patients (46%) in misoprostol group and no patient in oxytocin group. [Table 3](#t3-epj-05-713){ref-type="table"} compares drug side effects in two study groups. As shown in [Table 3](#t3-epj-05-713){ref-type="table"} the rate of nausea and vomiting is higher in misoprostol group. Additional procedures and actions were needed in 31 patients (62%) in misoprostol group and 32 patients (64%) in oxytocin group. This difference wasn't statistically significant (P=0.5). [Table 4](#t4-epj-05-713){ref-type="table"} compares the need for additional procedures and actions in two study groups.

4.. Discussion
==============

This study compares misoprostol with oxytocin in 2^nd^ trimester pregnancy termination. As shown in this study misoprostol is more effective in 2^nd^ trimester pregnancy termination in comparison to oxytocin. Higher rates of unsuccessful treatment were reported in oxytocin group. Also in patients with successful pregnancy termination, the mean duration of the termination was shorter in misoprostol group in comparison to oxytocin group. Several studies have confirmed the effectiveness of misoprostol ([@b1-epj-05-713], [@b13-epj-05-713], [@b15-epj-05-713], [@b24-epj-05-713], and [@b25-epj-05-713]). Also studies on misoprostol dosage and different treatment regimens are conducting ([@b12-epj-05-713]). Few studies have compared the effectiveness of misoprostol and oxytocin and oxytocin is usually used in combination with misoprostol. Despite this, one study has compared concentrated oxytocin with prostaglandin E2 in pregnancy termination have reported lower rates of fever and gastrointestinal side effects in oxytocin group. The most important side effects of misoprostol are gastrointestinal side effects such as nausea, vomiting, abdominal cramp, and diarrhea ([@b1-epj-05-713]). Our study confirms this finding and the rate of nausea and vomiting was higher in misoprostol group in our study.

Ramin et al. have reported similar findings. They have reported the superiority of high dose of misoprostol in comparison to oxytocin in 2^nd^ trimester ([@b26-epj-05-713]). This effectiveness was shown in lowering the duration of pregnancy termination and increasing the rate of the patients' delivery within 24 hours after treatment. Previous studies have shown that the combination of misoprostol and oxytocin is more effective in comparison to misoprostol alone in pregnancy termination. Owen et al have reported the success rate of 67% for vaginal 200mcg misoprostol every 12 hours. The researchers in this study have used the similar dose of the misoprostol but have reported the higher rate of treatment success in comparison to our study. The lower sample size in this study caused statistically insignificant differences despite the higher difference of the treatment success rates. Thirty patients were studied by Owen et al. they have used low dose vaginal prostaglandin E2 in combination to oxytocin. The authors concluded that no treatment is satisfactory for the patients in these two groups ([@b27-epj-05-713]).

Higher dosages of misoprostol in combination with oxytocin were associated with higher success rate. A success rate of 96.7% is reported for both groups in the study of the comparison of 600mcg initial misoprostol dosage followed by 400mcg every 6 hours and combination of misoprostol and oxytocin after 24 hours follow up in 120 patients ([@b28-epj-05-713]). There was no statistically significant difference between two groups in need for additional actions and procedures. Further analysis showed higher rate of need for additional misoprostol dosage in oxytocin group, but lower rate of curettage.

In summary, our findings support misoprostol usage for 2^nd^ trimester pregnancy termination. Although misoprostol is associated with higher rate of side effects, but is more effective for treatment of these patients. Also it should be noted that misoprostol side effects in our study and similar studies are mild and self limited gastrointestinal and nausea and vomiting with isn't life threatening. A large percentage of the patients in oxytocin group needed for additional misoprostol dosage, but if they received the additional dosage they had lower rates of need for curettage. This finding supports the possibility of better response to treatment in combination of misoprostol and oxytocin. More studies is still needed to answer the questions about effectiveness of combination therapies and also rout of administration of misoprostol is needed ([@b2-epj-05-713], [@b22-epj-05-713], and [@b29-epj-05-713]). Sample size and no long follow up of the patients for side effects were main limitations of the study. Pregnancy termination in Iran is limited to medical indications or IUFD. Also there is limitation in access to misoprostol in Iran.

5.. Conclusion
==============

Although misoprostol is more effective than oxytocin in 2^nd^ trimester pregnancy termination, but it is associated with higher rate of drug side effects. Therefore more studies on the combination of misoprostol and oxytocin treatment are needed.
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###### 

Baseline characteristics

  Baseline characteristics   Misoprostol    Oxytocin       
  -------------------------- -------------- -------------- ----------
  Age                        22.68 ± 6.6    26.50 ± 5.15   
  Gestational age            18.94 ± 4.27   17.48 ± 2.63   
  Fetal life situation       Alive          26 (52%)       27 (54%)
  Dead                       24 (48%)       23 (46%)       
  Cause of termination       Fetal death    24 (48%)       23 (46%)
  Fetal anomalies            26 (52%)       21 (42%)       
  Maternal problems          0 (0%)         6 (12%)        

###### 

Situation of pregnancy termination in two groups

  Pregnancy termination    Misoprostol   Oxytocin   P value
  ------------------------ ------------- ---------- ---------
  No termination           1 (2%)        22 (44%)   \<0.001
  Complete termination     19 (38%)      18 (36%)   \<0.001
  Incomplete termination   30 (60%)      10 (20%)   \<0.001

###### 

Comparison of drug side effects in two study groups

  Side effects         Misoprostol   Oxytocin   P value
  -------------------- ------------- ---------- ---------
  Nausea               13 (26%)      0 (0%)     \<0.001
  Vomiting             7 (14%)       0 (0%)     0.006
  Diarrhea             4 (8%)        0 (0%)     0.059
  Abdominal cramping   0 (0%)        0 (0%)     0.121
  Vaginal bleeding     0 (0%)        0 (0%)     \-
  Tachycystol          0 (0%)        0 (0%)     \-

###### 

Additional procedures and actions in two study groups

  Additional procedures           Misoprostol   Oxytocin   P value
  ------------------------------- ------------- ---------- ---------
  Curettage                       18 (36%)      7 (14%)    0.01
  Additional misoprostol dosage   13 (26%)      25 (50%)   0.011
  Hysterotomy                     0 (0%)        0 (0%)     \-
